Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancerYoshikazu Nagase(The University of Osaka), Tadashi Kimura(Osaka University)BMC CancerJune 21, 202210.1186/s12885-022-09789-6Cited by 7SaveCiteExport RISWatch citationsRelated PapersExosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells|BMC Cancer|2018|148Patient-Derived Exosomes as siRNA Carriers in Ovarian Cancer Treatment|Cancers|2024|17Patient-Derived Xenograft Mouse Model of a Rare Gynecologic Malignancy: Personalized Medicine for the Treatment of Mesonephric-Like Adenocarcinoma|Cureus|2025|0